What is Akeso?
Akeso, Inc. operates as a specialized biopharmaceutical enterprise dedicated to the research and development of innovative antibody drugs. Central to its competitive advantage is the ACE Platform, an end-to-end R&D engine that integrates advanced technologies such as Tetrabody and Dual-Shield ADCT. These proprietary tools allow the company to address significant unmet clinical needs in the treatment of cancer, metabolic diseases, and autoimmune disorders.
By maintaining a focus on both domestic and international markets, Akeso has established a robust framework for collaborative product development and licensing. The company's business model is designed to generate both commercial and social value, positioning it as a vital contributor to the global healthcare ecosystem. Through its commitment to affordable, high-quality therapeutic solutions, Akeso continues to attract significant attention from institutional investors focused on long-term life sciences growth.
How much funding has Akeso raised?
Akeso has raised a total of $422.2M across 4 funding rounds:
Series A
$19.5M
Series B
$2.7M
Series D
$150M
Share Placement
$250M
Series A (2015): $19.5M with participation from Shenzhen Capital Group, CCB Capital, and Qianhai Xino
Series B (2017): $2.7M led by ShenZhen GTJA Investment Group
Series D (2019): $150M supported by Loyal Valley Capital, Sino Biopharmaceutical,, OrbiMed, AIHC Capital, and Lake Bleu Capital
Share Placement (2024): $250M, investors not publicly disclosed
Key Investors in Akeso
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms. The firm leverages deep expertise in life sciences to support companies through various stages of development, from early-stage ventures to established organizations.
Shenzhen Capital Group
A prominent venture capital firm based in China, specializing in supporting high-growth technology and industrial enterprises through strategic equity investments.
Loyal Valley Capital
A private equity firm focused on identifying and investing in industry-leading companies within the Chinese market, with a particular emphasis on healthcare and consumer sectors.
What's next for Akeso?
With the recent influx of $250M, Akeso is well-positioned to transition into a new phase of operational expansion and clinical advancement. The strategic focus will likely center on accelerating the late-stage clinical trials of its lead candidates while further refining the efficiency of the ACE Platform. As the company scales, management is expected to prioritize the expansion of its international licensing footprint, leveraging existing partnerships to penetrate key global markets.
The current funding environment suggests that Akeso will continue to utilize its capital to optimize its manufacturing processes and strengthen its commercial infrastructure. By maintaining a rigorous focus on scientific excellence and strategic market positioning, the company is poised to navigate the complexities of the global biopharmaceutical landscape, ultimately aiming to deliver transformative treatments to patients worldwide while maximizing shareholder value.
